1 , mycophenolic acid (MPA), selenazofurin, or tiazofurin.

2  the active metabolite of the antitumor drug tiazofurin.

3 of nicotinamide riboside and the cancer drug tiazofurin.

4 e the effects of GTP on in situ TG activity, tiazofurin, a drug that selectively decreases GTP levels

5                                        Novel tiazofurin adenine dinucleotide (TAD) analogues 25-33 co

6 e 5'-monophosphate (MMP), and beta-methylene-tiazofurin adenine dinucleotide (TAD) were determined.

7 ticancer agent tiazofurin to its active form tiazofurin adenine dinucleotide (TAD).

8                                              Tiazofurin, an important inhibitor of inosine 5'-monopho

9                         For T. foetus IMPDH, tiazofurin and ADP are extraordinarily synergistic.

10  well as the synergistic interaction between tiazofurin and ADP differ significantly from those of th

11 homonas foetus and human type 2 IMPDHs using tiazofurin and ADP, which bind in the nicotinamide and a

12 lls an order of magnitude more potently than tiazofurin, and MAD analogues were resistant to glucuron

13 ntial, the most prominent being pyrazofurin, tiazofurin, and selenazofurin.

14 -dependent proteolysis due to the effects of tiazofurin, because in vitro GTP protects tTG against pr

15 cells (IC50 = 1.1 microM) more potently than tiazofurin (IC50 = 12.4 microM) or mycophenolic acid (IC

16  the structural mechanism for adenylation of tiazofurin nucleotide.

17 ine as a target and mycophenolic acid (MPA), tiazofurin, or ribavirin, which are inhibitors of IMP de

18                                          The tiazofurin resistance is mainly associated with the low

19  SH-SY5Y cells with a combination of MTX and tiazofurin resulted in significantly less in situ TG act

20 metabolic conversion of the anticancer agent tiazofurin to its active form tiazofurin adenine dinucle